New investigations on retatrutides, a dual activator for glucagon-like peptide-1 and gastric inhibitory polypeptide, suggest significant findings in managing obesity and type 2 glucose intolerance. Preliminary evidence from clinical trials reveal notable reductions in body bulk and enhanced gluco